Billing and Coding: MolDX: Oncotype DX® Colon Cancer Assay Update

The Oncotype DX Colon Cancer Assay (CPT 81525) is used to predict recurrence risk in patients with Stage II colon cancer and is billed as mRNA expression of 12 genes. Claims must report CPT 81525 with Days/Unit = 1, include the appropriate DEX Z-Code™ identifier adjacent to the CPT in specified Part A/Part B claim fields (SV101-7/SV202-7 or NTE; Loop 2400/Box 19 for Part B; Line SV202-7/Block 80 for Part A), and list the appropriate ICD-10-CM diagnosis code(s).

"Oncotype DX Colon Cancer Assay is intended to predict recurrence risk for patients with Stage II colon cancer."

Sign up to see full coverage criteria, indications, and limitations.